With a second positive phase 3 trial in hand, Sanofi and Regeneron have said they plan to file for approval of Dupixent in chronic obstructive pulmonary disease (COPD), a
France’s financial prosecutor has reportedly launched an investigation into Sanofi’s “financial communication” surrounding the launch of its biggest-selling drug Dupixent.
Almirall is within sniffing distance of EU approval for its IL-13 inhibitor lebrikizumab for atopic dermatitis, setting up a challenge to Sanofi and Regeneron’s market-lea
In a small sign of a possible improvement in the sluggish biotech initial public offering (IPO) market, Apogee Therapeutics has said it expects gross proceeds of $300 mill
Sanofi and Regeneron have built their case for Dupixent as a first biological therapy for chronic obstructive pulmonary disease (COPD) at the American Thoracic Society (AT
Sanofi and Regeneron acknowledged that testing their inflammatory disease blockbuster Dupixent in chronic obstructive pulmonary disease (COPD) was likely to be high-risk w
MSD and partner Moderna have started a late-stage trial of their personalised cancer vaccine V940 as a combination with MSD’s PD-1 inhibitor Keytruda for patients with non
On 1st October, the roll-out of the National Contract Value Review (NCVR) process marked a pivotal moment in the trajectory of clinical research in the UK, introducing a standardised, natio